Kardigan Inc. filed for a US initial public offering that will help fund three late-stage drugs that target the root cause of cardiovascular diseases.
Led by a team including the former managers of MyoKardia Inc. prior to its $13.1 billion acquisition by Bristol-Myers Squibb Co. in 2020, the firm is developing separate drugs to treat genetic dilated cardiomyopathy, calcific aortic valve stenosis and acute severe hypertension, according to its filing Tuesday with the US Securities and Exchange Commission.
The Princeton, New Jersey-based company had a net loss of $56.1 million in the first quarter of 2026, compared with a net ...
